Copeland Capital Management LLC Sells 410 Shares of Eli Lilly and Company (NYSE:LLY)

Copeland Capital Management LLC cut its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,682 shares of the company's stock after selling 410 shares during the quarter. Copeland Capital Management LLC's holdings in Eli Lilly and Company were worth $17,908,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of LLY. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter valued at about $43,000. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter valued at about $48,000. Highline Wealth Partners LLC raised its position in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after purchasing an additional 24 shares during the last quarter. Capital A Wealth Management LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at about $63,000. Finally, Bellwether Advisors LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at about $66,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on LLY. Guggenheim reiterated a "buy" rating and issued a $936.00 target price on shares of Eli Lilly and Company in a research report on Friday, June 20th. Wall Street Zen downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Trading Down 2.4%

NYSE LLY opened at $776.18 on Friday. The company has a market cap of $735.61 billion, a price-to-earnings ratio of 63.16, a P/E/G ratio of 1.13 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The business has a 50 day moving average price of $780.19 and a 200-day moving average price of $799.96. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. Eli Lilly and Company's dividend payout ratio is 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.